Investor Presentation - First Six Months of 2021
11
Investor presentation First six months of 2021
Obesity care sales grew by 34% in the first half of 2021
Reported sales split in operational units
DKK billion
Branded AOM TRX in the US
TRX count (000s)
2.4
90% 32
42%
3%1
34%
67%
1.8
24
60%
1.2
0.6
16
30%
8
0
0%
0
2019
2020
2021
Jan
2019
INAO IO
Market share (RHS)
-
SaxendaⓇ
Growth at CER
32.0
прир
Wegovy™ launch in the US
ONCE-WEEKLY
wegovy™
semaglutide injection
Novo NordiskⓇ
11.5
8.1
•
> 8,000 total scripts 5 weeks after launch
Market access has progressed
More than 50% of Wegovy™
prescriptions are new to the AOM class
Jan
2020
Jan
July
2021 2021
Branded AOM Market
1 Annual growth at CER. Each TRX data points represents one week of data
- Wegovy™
EMEA: Europe, Middle East and Africa, NAO: North America operations, IO: International operations, RHS: Right hand side axis
Note: Sales growth at constant exchange rates; AOM: Anti-Obesity Medications (includes Wegovy TM, SaxendaⓇ, Qsymia and Contrave)
Source: IQVIA NPA - TRX data, Weekly (ending 23 July 2021)View entire presentation